Rosen Law Firm Investigates Disc Medicine, Inc. Securities
Rosen Law Firm is investigating potential securities claims on behalf of Disc Medicine, Inc. shareholders. The inquiry stems from allegations that the company may have issued materially misleading business information.
Rosen Law Firm, a global investor rights law firm, is continuing its investigation into potential securities claims against Disc Medicine, Inc. (NASDAQ: IRON). The investigation concerns allegations that Disc Medicine may have provided materially misleading business information to the investing public.
The inquiry follows a Complete Response Letter (CRL) issued by the U.S. Food and Drug Administration (FDA) on February 13, 2026. The FDA stated it could not approve Disc Medicine's new drug application for its bitopertin program due to uncertainties requiring additional evidence.
Following this news, Disc Medicine's stock price fell by 22% on February 13, 2026. Rosen Law Firm is preparing a class action lawsuit to seek recovery for investor losses. Shareholders who purchased Disc Medicine securities are encouraged to contact the firm for information regarding the class action.
Rosen Law Firm represents investors globally and focuses on securities class actions and shareholder derivative litigation. The firm has a track record of recovering significant amounts for investors.